Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.
Auteurs : Mileva M, Wimana Z, Flamen P, Karfis I
Année : 2021
Journal : World J Nucl Med
Volume : 20
Pages : 316-318